256 Newsroom — Uganda's Digital News Infrastructure
Business

Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns - BioPharma Dive

Published by Biopharmadive.com By Gwendolyn Wu · 1 September 2026 at 11:22
Share
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns - BioPharma Dive
Image · Biopharmadive.com

What the report says

The deaths of three study participants led Novartis to halt development of rap-cel in multiple indications, while “transient” side effects pushed Bristol Myers to voluntarily pause its zola-cel program.

Read the full report at Biopharmadive.com →

Loading debate for this article…

Other publishers covering this story

No additional verified coverage is currently clustered with this report.

More stories by this journalist

Other publications from this journalist — open any story without leaving the article page.

No other published stories from this publisher yet.

Related reporting

Report highlights role of generic drugmakers in expanding medicine access in AfricaThe Observer BRICS 2026: New Delhi prepares for a summit that could reshape the Global SouthNile Post 256 Newsroom Africa Urged to Turn Regional Partnerships Into Trade, Investment - chimpreports.comChimpReports 256 Newsroom Rukungiri: Police Arrest 30-Year-Old Businesswoman for Defiling Teenage Boy - chimpreports.comChimpReports Uganda Unveils Pearl Sweet Crude at APPEC 2026 as First Oil NearsNile Post Fresh Dispute Erupts Over Wakiso Market Stall AllocationNile Post